The compounded GLP-1 ban: is compounded semaglutide legal in 2026?

If you have been using a compounded version of semaglutide or tirzepatide, the rules changed in 2025 and the FDA proposed to tighten them further in 2026. This page is a plain, dated walk-through of what actually happened, sourced to the FDA’s own documents — not a guide to obtaining any product.

A note on what this page grades: most Evidence Library pages weigh scientific claims on the Evidence Ladder. Here the core facts are regulatory record — published dates, orders, and a Federal Register proposal — so they sit on the established rung as a matter of documentation, not study quality. The safety reasoning that follows is the more uncertain part, and is flagged as such.

Is compounded semaglutide legal in 2026?

It is sharply restricted, and the legal basis that allowed widespread compounding is gone. Compounded copies of semaglutide and tirzepatide were never FDA-approved products; they were permitted mainly because the brand-name drugs were on the FDA drug shortage list, which opens a temporary compounding pathway. Once the FDA declared those shortages resolved in 2025, that pathway closed on set enforcement dates. In April 2026 the FDA proposed to also keep these molecules off the 503B bulks list, which would remove the remaining route for large outsourcing facilities to compound them from bulk drug substance.

So the honest answer in mid-2026 is: the broad “shortage era” access has ended, and a proposal is pending that would further narrow what is permitted. The molecules themselves remain FDA-approved as brand-name medicines (semaglutide as Ozempic, Wegovy and Rybelsus; tirzepatide as Mounjaro and Zepbound; liraglutide as Saxenda and Victoza). The dispute is about compounded versions, not the approved drugs.

What happened — the dated timeline

Date	Event
2022	Semaglutide and tirzepatide added to the FDA drug shortage list, opening the compounding pathway
Dec 19, 2024	FDA affirms the tirzepatide shortage is resolved
Feb 18, 2025	Enforcement deadline: 503A pharmacies must stop compounding tirzepatide
Feb 21, 2025	FDA declares the semaglutide shortage resolved
Mar 19, 2025	Enforcement deadline: 503B facilities must stop compounding tirzepatide
Apr 22, 2025	Enforcement deadline: 503A pharmacies must stop compounding semaglutide
May 22, 2025	Enforcement deadline: 503B facilities must stop compounding semaglutide
Apr 30, 2026	FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list — finding no clinical need
May 1, 2026	Proposal published in the Federal Register; public comment period opens
Jun 26, 2026	FDA extends the public comment period by 30 days
Jul 30, 2026	Extended comment period closes (original deadline was Jun 29); FDA then weighs comments before a final determination

As of this page’s review date (June 30, 2026), the 503B proposal is not final, and its public comment period is still open — the FDA extended the original June 29 deadline by 30 days to July 30, 2026.

What is the difference between 503A and 503B compounding?

These are two different legal pathways, and the news often blurs them.

	503A	503B
Who	State-licensed pharmacies / physicians	Registered “outsourcing facilities”
Scale	Patient-specific prescriptions	Larger batches, can ship to clinics
Oversight	State boards of pharmacy	FDA, including cGMP requirements
Bulk substances	Tied to shortage/other narrow conditions	Allowed only if on the 503B bulks list

The April 2026 proposal speaks specifically to the 503B bulks list. Patient-specific 503A compounding still exists, but it has its own legal limits — it cannot lawfully be used to make what is “essentially a copy” of an available approved drug, and a narrow medical reason (not cost or convenience) is what the rules contemplate. This page does not advise on individual eligibility; that is a clinician-and-pharmacist question.

Why did the FDA say there is “no clinical need”?

The FDA framed its 2026 proposal around a distinction between clinical need and economic need. After reviewing nominations to add these substances to the 503B bulks list, the agency said it did not identify a clinical need for outsourcing facilities to compound them from bulk — because FDA-approved versions are commercially available. Lower cost, by itself, is not treated as a clinical need under the statute. That is the crux of the debate: patients and some compounders point to price and access, while the FDA’s stated lens is drug-approval integrity and safety.

What does this mean for safety?

This is where certainty drops, and the page says so. There is no systematic surveillance of compounded or grey-market GLP-1 products, so the true rate of mislabeling, wrong concentration, or contamination is unknown — a gap, not a reassurance. What is well established is the principle from Chapter 21: the same molecule name does not guarantee the same purity, dose accuracy, sterility, or recourse if something goes wrong. Approved medicines carry manufacturing standards and post-market surveillance precisely because those steps catch identifiable harms; products made outside the regulated chain do not inherit those protections automatically.

There is also a hazard on the other side. Stopping a GLP-1 abruptly — out of fear that a product is now “illegal,” or because a compounded supply is suddenly cut off — is itself a change worth discussing first. For someone using it for type 2 diabetes, an unplanned gap can mean losing blood-sugar control. This page does not tell anyone to start, stop, or continue any medicine; it only points out that an interruption is a clinician conversation, not a snap decision.

Frequently asked questions

Does the April 30, 2026 proposal make compounded GLP-1s illegal everywhere right now? No. It is a proposal about the 503B bulks list, published May 1, 2026, with a public comment period that the FDA extended to July 30, 2026 (the original deadline was June 29) — still open as of this review. It is not a final rule, and it does not by itself change the 503A pathway.

Were compounded versions ever FDA-approved? No. Compounded drugs are not FDA-approved. During the shortage they were permitted under a temporary pathway, not approved for safety and efficacy the way brand-name products are.

Is the brand-name medicine affected? No. Semaglutide, tirzepatide and liraglutide remain approved as brand-name drugs. The regulatory action concerns compounded copies, not the approved products.

Why is liraglutide on the list too? The FDA’s proposal names all three GLP-1 molecules — semaglutide, tirzepatide and liraglutide — as substances it is proposing to keep off the 503B bulks list.

Could the proposal change after the comment period? Yes. The FDA said it will consider submitted comments before a final determination. A proposal can be finalized, modified, or not finalized.

Questions to ask a clinician

• Given my situation, what FDA-approved options are appropriate, and how do we access them?
• If I am currently using a compounded version, how should we plan any transition safely?
• What are the legitimate, regulated pathways for my prescription going forward?
• If cost is my barrier, what assistance programs or covered alternatives exist?
• How will we monitor my response and safety through any change in product?

Red flags / when to seek care

A change in product — strength, formulation, or source — is exactly when problems can surface. Contact a clinician promptly, or seek urgent care for severe symptoms:

• Severe or persistent abdominal pain, especially radiating to the back with repeated vomiting — a possible sign of pancreatitis.
• Upper-right abdominal pain, fever, or yellowing of the skin or eyes — possible gallbladder disease.
• A distended belly with vomiting and no bowel movements — possible bowel obstruction.
• Signs of dehydration from prolonged vomiting or diarrhea — dizziness, very dark or scant urine, confusion.
• Any reaction that seems out of proportion to what you experienced before — unexpected injection-site reactions, or symptoms that do not match the labeled product — which can signal a product-quality problem worth reporting to your clinician and to the FDA’s MedWatch program.

This page describes regulation; it does not prescribe. It contains no doses, no sourcing, and is not a substitute for the clinician who knows your history.